Relapsed/Refractory Hematological Malignancies
1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Chia Tai TianQing Pharmaceutical GroupChina - Lianyungang
1 programTQB3473PHASE_11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Ascentage PharmaAPG-3288
Qilu PharmaceuticalQLS2313
Chia Tai TianQing Pharmaceutical GroupTQB3473
Clinical Trials (3)
Total enrollment: 361 patients across 3 trials
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Start: Mar 2026Est. completion: Dec 2031180 patients
Phase 1Not Yet Recruiting
A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies
Start: Jan 2026Est. completion: Feb 2028124 patients
Phase 1Not Yet Recruiting
A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies
Start: Oct 2020Est. completion: Jun 202257 patients
Phase 1Unknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.